PCN24 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

Cost Effectiveness ◽

Health Care System ◽

Metastatic Breast ◽

Private Health Care ◽

System Perspective ◽

PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

Value in Health ◽

10.1016/j.jval.2020.08.206 ◽

2020 ◽

Vol 23 ◽

pp. S433-S434

Author(s):

G. Vondeling ◽

E. Palaka ◽

C. Livings ◽

J. Naik ◽

W. Sullivan

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Novel Therapies ◽

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Cited By ~ 1

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Cost-Effectiveness Analysis of Fulvestrant in the Treatment of Metastatic Breast Cancer in Second-Line Chemotherapy

Value in Health ◽

10.1016/j.jval.2014.08.2289 ◽

2014 ◽

Vol 17 (7) ◽

pp. A637

Author(s):

I. Krysanov ◽

V. Krysanova

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Second Line ◽

Second Line Chemotherapy ◽

Effectiveness Analysis ◽

Line Chemotherapy

PCN7 METASTATIC BREAST CANCER TREATMENT PATTERNS AND COSTS OF OUTPATIENT CARE UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

Value in Health ◽

10.1016/s1098-3015(10)75334-1 ◽

2009 ◽

Vol 12 (7) ◽

pp. A493-A494

Author(s):

V Teich ◽

N Teich ◽

M Nita ◽

BM Donato ◽

R Rached ◽

...

Keyword(s):

Breast Cancer ◽

Health Care ◽

Cancer Treatment ◽

Outpatient Care ◽

Metastatic Breast ◽

Breast Cancer Treatment ◽

Treatment Patterns ◽

Private Health Care ◽

System Perspective

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

Hormone Receptor Positive ◽

Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e11531 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e11531-e11531

Author(s):

Marie-Justine Paillard ◽

Elsa Curtit ◽

Virginie Nerich ◽

Laurent Cals ◽

Fernando Bazan ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Retrospective Analysis ◽

Metastatic Breast ◽

PIN17 COST-EFFECTIVENESS ANALYSIS OF THE NEW PCV-13 VACCINE WHEN COMPARED TO NO VACCINATION FROM A PUBLIC HEALTH-CARE SYSTEM PERSPECTIVE IN HONG KONG

Value in Health ◽

10.1016/s1098-3015(11)73297-1 ◽

2010 ◽

Vol 13 (7) ◽

pp. A549

Author(s):

KK Lee ◽

DP Chow

Keyword(s):

Public Health ◽

Health Care ◽

Hong Kong ◽

Cost Effectiveness ◽

Health Care System ◽

Public Health Care ◽

Public Health Care System ◽

System Perspective ◽

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain: Management in the Later Lines of Therapy

Value in Health ◽

10.1016/j.jval.2015.03.1175 ◽

2015 ◽

Vol 18 (3) ◽

pp. A203 ◽

Cited By ~ 1

Author(s):

U. Majethia ◽

G. Tremblay ◽

I. Kontoudis ◽

J. DeRosendo

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

The Breast ◽

10.1016/j.breast.2019.11.012 ◽

2020 ◽

Vol 49 ◽

pp. 141-148 ◽

Cited By ~ 2

Author(s):

Vakaramoko Diaby ◽

Hussain Alqhtani ◽

Sascha van Boemmel-Wegmann ◽

Ching-Yu Wang ◽

Askal Ayalew Ali ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Effectiveness Analysis ◽

Her 2 ◽

Treatment Sequences

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s41850 ◽

2013 ◽

pp. 125 ◽

Cited By ~ 14

Author(s):

Carlo Lazzaro ◽

Roberto Bordonaro ◽

Francesco Cognetti ◽

Fabi ◽

Sabino De Placido ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽